Management Team

Gaby Salem


Gaby is the founder and Managing Director of Wharton Asset Management, a private London based family office specialising in private equity investment in diverse sectors including healthcare and biotechnology. Gaby has over 20 years of experience in finance and investment. He is the co-founder of Rexgenero bringing together the licence partner, the investors and management team within Rexgenero. He represents the principal shareholders and funders of Rexgenero.

Joe Dupere

Chief Executive Officer

Joe Dupere was appointed as Chief Executive Officer of Rexgenero in February 2015. Joe has more than 20 years of business development, M&A, operational and research management experience in the biopharmaceutical and investment banking sectors. Prior to Rexgenero, Joe was Head of Business Development at Riemser Pharma GmbH, Director of Healthcare Investment Banking at Deutsche Bank and previously Vice President of Healthcare Investment Banking at Bear Stearns. He has been a Senior Scientist in CNS discovery research at Glaxo Wellcome.
Joe received a First Class B.Sc. in Neuroscience from the University of Manchester and a Ph.D. in Pharmacology from the University of Bristol and an MBA from Cranfield School of Management.

Edwin Wagena

Chief Operating Officer

Edwin Wagena was appointed as Chief Operating Officer of Rexgenero in April 2015. Edwin has more than 15 years of experience in pharmaceutical development both in academia and the pharmaceutical industry. He has strong knowledge and experience with the development of advanced-therapy medicinal products (ATMPs).

Prior to Rexgenero, Edwin served as Chief Development Officer and Senior Vice President at Kiadis Pharma B.V. Before he joined Kiadis Pharma in 2008, Edwin worked in the clinical development departments of Astellas Pharma and Solvay Pharmaceuticals. Edwin is currently the Regional Vice-President in Europe for the International Society for Cellular Therapy (ISCT).

Edwin received his M.A. in Health Sciences from the University of Groningen, the Netherlands and he obtained his Ph.D. at the University Hospital Maastricht/Maastricht University, the Netherlands.

Liesbeth de Jong 

Vice President, Manufacturing and Research & Development

Liesbeth joined Rexgenero in January 2016 as Vice President, Manufacturing and R&D. Liesbeth in an expert in the development and manufacturing of cellular therapies both in biopharmaceutical companies and academic research. Prior to Rexgenero Liesbeth was Fellow Process Development at the Cell and Gene Therapy Unit at Novartis, Head of Manufacturing / Director of Process Development at Kiadis Pharma BV and Scientist at Chrongen Inc. Liesbeth received a MSc in Biology from the Research Institute of Toxicology at the University of Utrecht and a PhD from the Department of Molecular Biology at the University of Amsterdam.

Karen Reitsma

Vice President, Clinical and Regulatory Development

Karen joined Rexgenero in October 2016 as Vice President Clinical and Regulatory Development. Karen has extensive experience in the development of cell therapies in Europe and the US. Prior to Rexgenero, Karen was a Project Lead at HAL Allergy, Director Clinical Operations at Kiadis, Senior Project Manager at INC Research and Clinical Trial Manager at Merck Serono. Karen was also a Post-Doctoral Fellow at Nederlands Kanker Instituut (Netherlands Cancer Institute) and Vrije Universiteit (Free University) Amsterdam. Karen has a Ph.D. in Molecular Oncology and a degree in Medical Biology from the Vrije Universiteit, Amsterdam.